期刊
SMALL METHODS
卷 -, 期 -, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smtd.202201307
关键词
cancer vaccines; combination therapy; drug delivery; nanoparticles
Immunogenic cell death (ICD) activates the immune system to eliminate tumors. However, using chemotherapeutic drugs as ICD inducers in tumor immunotherapy faces challenges such as poor solubility, short circulation, non-specific distribution, and toxicity. Recent advances in nanotechnology and pharmaceutical formulation offer solutions to overcome these challenges.
Immunogenic cell death (ICD, also known as immunogenic apoptosis) of malignant cells is confirmed to activate the host immune system to prevent, control, and eliminate tumors. Recently, a range of chemotherapeutic drugs have been repurposed as ICD inducers and applied for tumor immunotherapy. However, several hurdles to the widespread application of chemotherapeutic ICD inducers remain, namely poor water solubility, short blood circulation, non-specific tissue distribution, and severe toxicity. Recent advances in nanotechnology and pharmaceutical formulation foster the development of nano drug delivery systems to tackle the aforementioned hurdles and expedite safe, effective, and specific delivery. This review will describe delivery barriers to chemical ICD inducers and highlight recent nanoformulations for these drugs in tumor immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据